Antibodies against viruses: passive and active immunization

Current Opinion in Immunology

Volumn 20, Issue 4, 2008, Pages 486-492

  Law, Mansun ^a   Hangartner, Lars ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD16 ANTIGEN; EPITOPE; FC RECEPTOR; GEMTUZUMAB OZOGAMICIN; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; IBRITUMOMAB TIUXETAN; IBRITUMOMAB TIUXETAN IN 111; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G3; MEMBRANE PROTEIN; MONOCLONAL ANTIBODY; MOTAVIZUMAB; NEUTRALIZING ANTIBODY; PALIVIZUMAB; POLYCLONAL ANTIBODY; RABIES VIRUS ANTIBODY; RADIOPHARMACEUTICAL AGENT; SARS CORONAVIRUS ANTIBODY; TOSITUMOMAB I 131; UNCLASSIFIED DRUG; VIRUS ANTIBODY; VIRUS ENVELOPE PROTEIN; VIRUS VACCINE;

ACTIVE IMMUNIZATION; ADAPTIVE IMMUNITY; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY ENGINEERING; ANTIVIRAL ACTIVITY; COMPLEMENT DEPENDENT CYTOTOXICITY; DRUG RECEPTOR BINDING; EBOLA VIRUS; HIGH RISK PATIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INFECTION RISK; INNATE IMMUNITY; NONHUMAN; ORGAN TRANSPLANTATION; PASSIVE IMMUNIZATION; REVIEW; SARS CORONAVIRUS; SMALLPOX; STOICHIOMETRY; VACCINATION REACTION; VIRION; VIRUS ATTACHMENT; VIRUS INFECTION; VIRUS NEUTRALIZATION; WEST NILE FLAVIVIRUS;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, VIRAL; EPITOPES; HUMANS; IMMUNIZATION, PASSIVE; NEUTRALIZATION TESTS; VACCINATION; VIRAL VACCINES; VIRUSES;

EID: 48549096762     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coi.2008.06.005     Document Type: Review

References (46)

1. Edghill-Smith Y., Golding H., Manischewitz J., King L.R., Scott D., Bray M., Nalca A., Hooper J.W., Whitehouse C.A., Schmitz J.E., et al. Smallpox vaccine-induced antibodies are necessary and sufficient for protection against monkeypox virus. Nat Med 11 (2005) 740-747. The relative contribution of humoral and cell-mediated responses in protection against smallpox following vaccination has been unclear. A major argument against humoral responses had been based on reported cases of protective immunity developed in vaccinated humans who failed to elicit rigorous antibody responses and in those who suffered from agammaglobuinemia. A similar argument is also commonly found today in other viral diseases where protection mechanism is unclear, for example, HCV. This study conclusively demonstrates that humoral, but not cell-mediated immunity, plays a central role in vaccine-induced protection.
2. Fang M., and Sigal L.J. Antibodies and CD8+ T cells are complementary and essential for natural resistance to a highly lethal cytopathic virus. J Immunol 175 (2005) 6829-6836
3. Putz M.M., Midgley C.M., Law M., and Smith G.L. Quantification of antibody responses against multiple antigens of the two infectious forms of Vaccinia virus provides a benchmark for smallpox vaccination. Nat Med 12 (2006) 1310-1315
4. Wu H., Pfarr D.S., Losonsky G.A., and Kiener P.A. Immunoprophylaxis of RSV infection: advancing from RSV-IGIV to palivizumab and motavizumab. Curr Top Microbiol Immunol 317 (2008) 103-123. This review summarizes the history and science of the development of the first MAb approved for prophylaxis against a human viral disease, RSV.
5. Desjarlais J.R., Lazar G.A., Zhukovsky E.A., and Chu S.Y. Optimizing engagement of the immune system by anti-tumor antibodies: an engineer's perspective. Drug Discov Today 12 (2007) 898-910
6. Parren P.W., and Burton D.R. The antiviral activity of antibodies in vitro and in vivo. Adv Immunol 77 (2001) 195-262
7. Pierson T.C., Xu Q., Nelson S., Oliphant T., Nybakken G.E., Fremont D.H., and Diamond M.S. The stoichiometry of antibody-mediated neutralization and enhancement of West Nile virus infection. Cell Host Microbe 1 (2007) 135-145. This study applied state-of-art knowledge learnt from crystallographic and cryo-electron microscopic modeling of WNV SUs to investigate the stoichiometry of antibody neutralization and enhancement of WNV. A number of closely related epitopes were fit onto the models to explain how epitope organization and accessibility influences antibody neutralization spatially.
8. Yang X., Kurteva S., Lee S., and Sodroski J. Stoichiometry of antibody neutralization of human immunodeficiency virus type 1. J Virol 79 (2005) 3500-3508
9. Hessell A.J., Hangartner L., Hunter M., Havenith C.E., Beurskens F.J., Bakker J.M., Lanigan C.M., Landucci G., Forthal D.N., Parren P.W., et al. Fc receptor but not complement binding is important in antibody protection against HIV. Nature 449 (2007) 101-104. The passive immunization experiments in this study demonstrate the importance of Fc-receptor-mediated effector functions in protections against vaginal challenge of macques with SHIV.
10. Walker B.D., and Burton D.R. Toward an AIDS vaccine. Science 320 (2008) 760-764
11. 2 in mice. Respir Res 7 (2006) 43
12. Palladino G., Mozdzanowska K., Washko G., and Gerhard W. Virus-neutralizing antibodies of immunoglobulin G (IgG) but not of IgM or IgA isotypes can cure influenza virus pneumonia in SCID mice. J Virol 69 (1995) 2075-2081
13. Mehlhop E., Ansarah-Sobrinho C., Johnson S., Engle M., Fremont D.H., Pierson T.C., and Diamond M.S. Complement protein C1q inhibits antibody-dependent enhancement of flavivirus infection in an IgG subclass-specific manner. Cell Host Microbe 2 (2007) 417-426
14. Hangartner L., Zellweger R.M., Giobbi M., Weber J., Eschli B., McCoy K.D., Harris N., Recher M., Zinkernagel R.M., and Hengartner H. Nonneutralizing antibodies binding to the surface glycoprotein of lymphocytic choriomeningitis virus reduce early virus spread. J Exp Med 203 (2006) 2033-2042
15. Holl V., Peressin M., Schmidt S., Decoville T., Zolla-Pazner S., Aubertin A.M., and Moog C. Efficient inhibition of HIV-1 replication in human immature monocyte-derived dendritic cells by purified anti-HIV-1 IgG without induction of maturation. Blood 107 (2006) 4466-4474
16. de Jong J.M., Schuurhuis D.H., Ioan-Facsinay A., Welling M.M., Camps M.G., van der Voort E.I., Huizinga T.W., Ossendorp F., Verbeek J.S., and Toes R.E. Dendritic cells, but not macrophages or B cells, activate major histocompatibility complex class II-restricted CD4+ T cells upon immune-complex uptake in vivo. Immunology 119 (2006) 499-506
17. Huber V.C., Lynch J.M., Bucher D.J., Le J., and Metzger D.W. Fc-receptor-mediated phagocytosis makes a significant contribution to clearance of influenza virus infections. J Immunol 166 (2001) 7381-7388
18. McCullough K.C., Parkinson D., and Crowther J.R. Opsonization-enhanced phagocytosis of foot-and-mouth disease virus. Immunology 65 (1988) 187-191
19. Jayasekera J.P., Moseman E.A., and Carroll M.C. Natural antibody and complement mediate neutralization of influenza virus in the absence of prior immunity. J Virol 81 (2007) 3487-3494
20. Ochsenbein A.F., Fehr T., Lutz C., Suter M., Brombacher F., Hengartner H., and Zinkernagel R.M. Control of early viral and bacterial distribution and disease by natural antibodies. Science 286 (1999) 2156-2159. This study demonstrates how pre-existing natural antibodies and complement are important to lower the initial burden and to prime the adaptive immune system.
21. Nimmerjahn F., and Ravetch J.V. Divergent immunoglobulin g subclass activity through selective Fc receptor binding. Science 310 (2005) 1510-1512
22. Oswald W.B., Geisbert T.W., Davis K.J., Geisbert J.B., Sullivan N.J., Jahrling P.B., Parren P.W., and Burton D.R. Neutralizing antibody fails to impact the course of Ebola virus infection in monkeys. PLoS Pathog 3 (2007) e9. This study demonstrates that although neutralizing antibodies can protect against Ebola virus in small animals, they fail to protect primates from lethal challenge with Ebola virus.
23. Ochsenbein A.F., Pinschewer D.D., Odermatt B., Carroll M.C., Hengartner H., and Zinkernagel R.M. Protective T cell-independent antiviral antibody responses are dependent on complement. J Exp Med 190 (1999) 1165-1174
24. Mehlhop E., Whitby K., Oliphant T., Marri A., Engle M., and Diamond M.S. Complement activation is required for induction of a protective antibody response against West Nile virus infection. J Virol 79 (2005) 7466-7477
25. Huber M., Fischer M., Misselwitz B., Manrique A., Kuster H., Niederost B., Weber R., von Wyl V., Gunthard H.F., and Trkola A. Complement lysis activity in autologous plasma is associated with lower viral loads during the acute phase of HIV-1 infection. PLoS Med 3 (2006) e441
26. Klasse P.J., and Sattentau Q.J. Mechanisms of virus neutralization by antibody. Curr Top Microbiol Immunol 260 (2001) 87-108
27. Zhu P., Chertova E., Bess Jr. J., Lifson J.D., Arthur L.O., Liu J., Taylor K.A., and Roux K.H. Electron tomography analysis of envelope glycoprotein trimers on HIV and simian immunodeficiency virus virions. Proc Natl Acad Sci U S A 100 (2003) 15812-15817
28. Yang X., Lipchina I., Cocklin S., Chaiken I., and Sodroski J. Antibody binding is a dominant determinant of the efficiency of human immunodeficiency virus type 1 neutralization. J Virol 80 (2006) 11404-11408
29. Parren P.W., Mondor I., Naniche D., Ditzel H.J., Klasse P.J., Burton D.R., and Sattentau Q.J. Neutralization of human immunodeficiency virus type 1 by antibody to gp120 is determined primarily by occupancy of sites on the virion irrespective of epitope specificity. J Virol 72 (1998) 3512-3519
30. Mukhopadhyay S., Kim B.S., Chipman P.R., Rossmann M.G., and Kuhn R.J. Structure of West Nile virus. Science 302 (2003) 248
31. Yang X., Kurteva S., Ren X., Lee S., and Sodroski J. Stoichiometry of envelope glycoprotein trimers in the entry of human immunodeficiency virus type 1. J Virol 79 (2005) 12132-12147
32. Karlsson Hedestam G.B., Fouchier R.A., Phogat S., Burton D.R., Sodroski J., and Wyatt R.T. The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus. Nat Rev Microbiol 6 (2008) 143-155
33. Burton D.R. Antibodies, viruses and vaccines. Nat Rev Immunol 2 (2002) 706-713
34. Traggiai E., Becker S., Subbarao K., Kolesnikova L., Uematsu Y., Gismondo M.R., Murphy B.R., Rappuoli R., and Lanzavecchia A. An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus. Nat Med 10 (2004) 871-875
35. Zhou T., Xu L., Dey B., Hessell A.J., Van Ryk D., Xiang S.H., Yang X., Zhang M.Y., Zwick M.B., Arthos J., et al. Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature 445 (2007) 732-737
36. Law M., Maruyama T., Lewis J., Giang E., Tarr A.W., Stamataki Z., Gastaminza P., Chisari F.V., Jones I.M., Fox R.I., et al. Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge. Nat Med 14 (2008) 25-27. This study demonstrates that it may be possible to protect against the highly heterogeneous HCV quasispecies using broadly NAbs.
37. Li Y., Migueles S.A., Welcher B., Svehla K., Phogat A., Louder M.K., Wu X., Shaw G.M., Connors M., Wyatt R.T., et al. Broad HIV-1 neutralization mediated by CD4-binding site antibodies. Nat Med 13 (2007) 1032-1034
38. Binley J.M., Wrin T., Korber B., Zwick M.B., Wang M., Chappey C., Stiegler G., Kunert R., Zolla-Pazner S., Katinger H., et al. Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J Virol 78 (2004) 13232-13252
39. Keck Z.Y., Machida K., Lai M.M., Ball J.K., Patel A.H., and Foung S.K. Therapeutic control of hepatitis C virus: the role of neutralizing monoclonal antibodies. Curr Top Microbiol Immunol 317 (2008) 1-38
40. Mascola J.R., D'Souza P., Gilbert P., Hahn B.H., Haigwood N.L., Morris L., Petropoulos C.J., Polonis V.R., Sarzotti M., and Montefiori D.C. Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccines. J Virol 79 (2005) 10103-10107
41. ter Meulen J., van den Brink E.N., Poon L.L., Marissen W.E., Leung C.S., Cox F., Cheung C.Y., Bakker A.Q., Bogaards J.A., van Deventer E., et al. Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants. PLoS Med 3 (2006) e237
42. de Kruif J., Bakker A.B., Marissen W.E., Kramer R.A., Throsby M., Rupprecht C.E., and Goudsmit J. A human monoclonal antibody cocktail as a novel component of rabies postexposure prophylaxis. Annu Rev Med 58 (2007) 359-368
43. Manning S.E., Rupprecht C.E., Fishbein D., Hanlon C.A., Lumlertdacha B., Guerra M., Meltzer M.I., Dhankhar P., Vaidya S.A., Jenkins S.R., et al. Human rabies prevention--United States, 2008: recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep 57 (2008) 1-28
44. Shields R.L., Namenuk A.K., Hong K., Meng Y.G., Rae J., Briggs J., Xie D., Lai J., Stadlen A., Li B., et al. High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J Biol Chem 276 (2001) 6591-6604
45. Pincus S.H., Fang H., Wilkinson R.A., Marcotte T.K., Robinson J.E., and Olson W.C. In vivo efficacy of anti-glycoprotein 41, but not anti-glycoprotein 120, immunotoxins in a mouse model of HIV infection. J Immunol 170 (2003) 2236-2241
46. Eren R., Ilan E., Nussbaum O., Lubin I., Terkieltaub D., Arazi Y., Ben-Moshe O., Kitchinzky A., Berr S., Gopher J., et al. Preclinical evaluation of two human anti-hepatitis B virus (HBV) monoclonal antibodies in the HBV-trimera mouse model and in HBV chronic carrier chimpanzees. Hepatology 32 (2000) 588-596